Labcorp Rolls Out Companion Diagnostic for Merck's Keytruda in Platinum-Resistant Ovarian Cancer

MT Newswires Live04-22

Labcorp (LH) has launched nationwide access to an FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer who may be eligible for treatment with Merck's (MRK) Keytruda, the company said Wednesday.

The Agilent-developed PD-L1 IHC 22C3 pharmDx test is the only FDA-approved companion diagnostic for this indication and helps clinicians identify eligible patients for Keytruda-based treatment regimens, Labcorp said.

Labcorp said the rollout is intended to expand access to precision testing and support treatment decisions for patients with limited options after developing resistance to platinum-based chemotherapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment